



**ULTRAMARINE &  
PIGMENTS LTD.**

MANUFACTURERS OF INORGANIC PIGMENTS

Ph: 0091 - 44- 26136700-04 (5 lines)  
exports@ultramarinepigments.net  
www.ultramarinepigments.net



24-07-2025

BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal street fort,  
Mumbai – 400 001

**Scrip Code: 506685**

Dear Sirs,

**Sub: Newspaper Publication – Extract of the unaudited financial results  
for the quarter ended 30<sup>th</sup> June, 2025**

**Ref: Regulation 47 of SEBI (Listing Obligations and Disclosure  
Requirements) Regulations, 2015**

We enclose herewith the copy of newspaper publication regarding extract of Unaudited financial results for the quarter ended 30<sup>th</sup> June, 2025, are published in the Economic Times and Maharashtra Times on 24<sup>th</sup> July, 2025.

The above mentioned information is available on the Company's Website:  
<https://ultramarinepigments.net/newspaper-publication/>

Kindly take the above information on record.

Thanking you  
Yours Faithfully,

For **Ultramarine & Pigments Limited**

  
Kishore Kumar Sahoo  
Company Secretary

Encl.: as above





## Years up for Launch

after patents expire in 2026

over the next decade.  
"We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation," said Israeli.  
On Wednesday, the company reported consolidated revenue for the first quarter at ₹5.48 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at ₹1.48 crore, up 2% YoY.  
Israeli said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product launches. The company's global generic revenue in Q1 FY26 stood at ₹5.52 crore, a growth of 10% year-on-year.

## Reply to Novo Nordisk's Plea

weight-loss drug semaglutide. The court's directive comes on the back of a plea by Novo Nordisk, which alleged patent infringement of its weight-loss drug.  
The drug is slated to lose its patents in March next year. In a May 29 order, the Delhi High Court had said the defendant did not have a license to sell the drug in India. -Our Bureau

## Over Replacing Ling Services

hence stands vacated," the court said.  
It added that post revocation of security clearance, all employees and equipment of the petitioner firm have been placed under the control of another company, Indo Thai Airport Services, which is now carrying out the ground handling and bridge mounting services at the Mumbai airport.  
"The petitioner firm has lost all physical access to the airport," the court said.

## Tata Consumer Q1 Profit Rises 10%; Tea, Salt Drive India Growth

Our Bureau

Bengaluru: Tata Consumer Products (TCPL) on Wednesday reported a 9.8% year-on-year jump in its consolidated revenue from operations for the quarter ended June 30 at ₹1,778.9 crore, while its profit after tax grew 10.2% to ₹346.4 crore.

The maker of Tata Tea and Tata Salt said its India business recorded double-digit growth in the quarter, driven by the tea and salt categories, though its ready-to-drink business volume growth was impacted by unseasonal rains.

The company's international business grew 5% at constant currency revenue growth.

Consolidated earnings before interest, taxes, depreciation and amortisation (Ebitda) declined by 8% to ₹615 crore due to higher tea costs in India and coffee price corrections in the non-branded segment, the company said.



Ebitda margin was down 250 basis points at 12.0%.

TCPL managing director Sunil D'Souza in an earnings call told analysts

that tea prices are currently 13-15% below last year and that he does not expect it to trend lower. "Coffee, while trending downwards, is not a uniform trend... There is still a bit of volatility there that we need to manage," he said.

While the company is still a relatively small player in coffee, the segment posted 83% volume growth and 67% value growth during the quarter, D'Souza said.

Group net profit, after exceptional items, rose 15% on year to ₹332 crore in the June quarter.



## ULTRAMARINE & PIGMENTS LIMITED

REGD. OFFICE : THIRUMALAI HOUSE, PLOT NO.101/102, SION MATUNGA ESTATE, ROAD NO.29, SION (EAST), MUMBAI 400 022.

CIN: L24224MH1960PLC011856, Tel.No.: 022-43686200, Fax No.: 022-24011699/24014754

Email Id: cs@uplamb.net, Website: <http://www.ultramarinepigments.net>

### EXTRACT OF THE UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2025

(₹ IN LAKHS)

| PARTICULARS                                                                                                                                     | STANDALONE    |            |            |            | CONSOLIDATED  |            |            |            |
|-------------------------------------------------------------------------------------------------------------------------------------------------|---------------|------------|------------|------------|---------------|------------|------------|------------|
|                                                                                                                                                 | Quarter Ended |            | Year Ended |            | Quarter Ended |            | Year Ended |            |
|                                                                                                                                                 | 30.06.2025    | 31.03.2025 | 30.06.2024 | 31.03.2025 | 30.06.2025    | 31.03.2025 | 30.06.2024 | 31.03.2025 |
|                                                                                                                                                 | Unaudited     | Audited    | Unaudited  | Audited    | Unaudited     | Audited    | Unaudited  | Audited    |
| Total income from Operations (net)                                                                                                              | 17,163        | 18,434     | 15,479     | 66,330     | 18,721        | 19,771     | 16,336     | 70,710     |
| Net Profit/(Loss) for the period before Tax (after Exceptional / Extraordinary Items)                                                           | 2,226         | 2,164      | 2,124      | 9,307      | 2,655         | 2,298      | 2,206      | 9,957      |
| Net Profit/(Loss) for the period after Tax (after Exceptional / Extraordinary Items)                                                            | 1,663         | 1,587      | 1,587      | 6,967      | 2,019         | 1,702      | 1,654      | 7,506      |
| Total Comprehensive Income for the period (Comprising of Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)) | 9,581         | (12,126)   | 13,620     | 8,306      | 9,937         | (12,031)   | 13,687     | 8,823      |
| Equity Share Capital                                                                                                                            | 584           | 584        | 584        | 584        | 584           | 584        | 584        | 584        |
| Reserves i.e. Other Equity (excluding Revaluation Reserves as shown in the Audited Balance Sheet of previous years)                             | -             | -          | -          | 95,573     | -             | -          | -          | 96,740     |
| Earning Per Share (of Rs. 2/- each) (for continuing and discontinued operations)                                                                |               |            |            |            |               |            |            |            |
| 1. Basic:                                                                                                                                       | 5.70          | 5.44       | 5.43       | 23.86      | 6.91          | 5.83       | 5.66       | 25.70      |
| 2. Diluted:                                                                                                                                     | 5.70          | 5.44       | 5.43       | 23.86      | 6.91          | 5.83       | 5.66       | 25.70      |

NOTE:

- The Audit Committee has reviewed these results and the Board of Directors have approved the above results at their meeting held on 23rd July, 2025.
- The above is an extract of the detailed format of Statement of Standalone and Consolidated Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Standalone and Consolidated Financial Results are available on the Stock Exchange website [www.bseindia.com](http://www.bseindia.com) also on the Company's website [www.ultramarinepigments.net](http://www.ultramarinepigments.net) and this can also be accessed through the QR Code given below.



Place : Chennai  
Date : 23rd July, 2025

ON BEHALF OF THE BOARD  
FOR ULTRAMARINE & PIGMENTS LIMITED  
Sd/-  
TARA PARTHASARATHY  
MANAGING DIRECTOR  
DIN: 07121058

Sheffield  
Hallam  
University

SHEFFIELD  
BUSINESS  
SCHOOL